Amylyx Pharmaceuticals shares surged 54.43% after the company reported favorable topline Phase 3 results for avexitide in post-bariatric hypoglycemia, while UBS set a $45 price target implying 36% upside from current levels. In the 78-participant, 16-week LUCIDITY study, once-daily 90 mg subcutaneous avexitide met the FDA-agreed primary objective by cutting the combined rate of Level 2 and Level 3 hypoglycemic episodes by 55% versus placebo and also met all secondary endpoints. Amylyx said avexitide was generally well-tolerated, with mostly mild to moderate adverse events including diarrhea and minor injection-site reactions, no serious treatment-related adverse events and no notable weight changes. The company plans to file a New Drug Application with the FDA before the end of 2026 and is preparing for a potential 2027 launch, while a 32-week open-label extension, an expanded access program and its cash runway into 2028 remain in place.